2E9 Stock Chart & Stats
€0.05
€0.00(0.00%)
At close: 4:00 PM EST
€0.05
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.11
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€41.01M
Enterprise Value€301.20M
Total Cash (Recent Filing)€145.63M
Total Debt (Recent Filing)€357.00K
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Aug 20, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding340,813,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.00
Price to Sales (P/S)13.68
P/FCF Ratio-4.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€1.44M
Bulls Say, Bears Say
Bulls Say
Commercialized Product (Strangvac)Owning and commercializing Strangvac provides a real, revenue-generating product and a clear go-to-market asset. Durable adoption by vets/owners can create recurring sales and a platform for geographic expansion; commercialization partners broaden market access and lower direct selling costs.
Low Leverage And Substantial EquityA low-debt, high-equity capital structure preserves strategic flexibility and reduces bankruptcy risk, giving management time to invest in commercialization or R&D. This buffer supports long-term product rollouts and cushions operating losses while limiting immediate refinancing pressure.
Improving Free Cash Flow TrajectoryAn improving FCF trend indicates progress in cash conversion and cost discipline, showing the business is moving toward narrower gaps between accounting losses and cash outflows. If sustained, this reduces funding needs and increases the chance of reaching self-funding operations over several quarters.
Bears Say
Heavy Cash BurnPersistent negative operating and free cash flow materially increases reliance on external capital. Over a multi-quarter horizon this can force dilutive equity raises or debt, constrain investment in commercialization, and gradually erode the equity cushion despite current low leverage.
Deep Negative MarginsNegative gross profit and extreme operating losses imply structural cost or pricing issues and prevent operating leverage. Without sustained margin recovery, the business cannot generate profits as scale increases, threatening long-term viability despite product commercialization.
Modest And Declining Revenue BaseA small and contracting revenue base limits the company's ability to absorb fixed costs and achieve scale economics. Dependence on a single commercial product and partner channels heightens concentration risk and makes durable growth more challenging absent new product approvals or expanded market penetration.
Intervacc AB News
2E9 FAQ
What was Intervacc AB’s price range in the past 12 months?
Intervacc AB lowest stock price was €0.01 and its highest was €0.11 in the past 12 months.
What is Intervacc AB’s market cap?
Intervacc AB’s market cap is €41.01M.
When is Intervacc AB’s upcoming earnings report date?
Intervacc AB’s upcoming earnings report date is Aug 20, 2026 which is in 46 days.
How were Intervacc AB’s earnings last quarter?
Intervacc AB released its earnings results on May 13, 2026. The company reported -€0.005 earnings per share for the quarter, the consensus estimate of -€0.005 by €0.
Is Intervacc AB overvalued?
According to Wall Street analysts Intervacc AB’s price is currently Overvalued.
Does Intervacc AB pay dividends?
Intervacc AB does not currently pay dividends.
What is Intervacc AB’s EPS estimate?
Intervacc AB’s EPS estimate is >-0.01.
How many shares outstanding does Intervacc AB have?
Intervacc AB has 340,813,200 shares outstanding.
What happened to Intervacc AB’s price movement after its last earnings report?
Intervacc AB reported an EPS of -€0.005 in its last earnings report, expectations of -€0.005. Following the earnings report the stock price went down -6.494%.
Which hedge fund is a major shareholder of Intervacc AB?
Currently, no hedge funds are holding shares in DE:2E9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intervacc AB
Intervacc AB (publ) is a Swedish biotechnology company primarily engaged in the research and development of innovative vaccines designed to combat bacterial infections in animal health. The firm's vaccine pipeline targets various animals, including horses, piglets, and dairy cows, with its key product, Strangvac, specifically developed to prevent equine strangles. Beyond its current offerings, Intervacc is also advancing vaccines against Streptococcus suis and Staphylococcus aureus infections. In addition to vaccine development, the company distributes veterinary medicines and provides essential diagnostic services in veterinary bacteriology to clinics and stud farms. Headquartered in Hägersten, Sweden, Intervacc serves customers across the Nordic countries and the Baltic states.
Technical Analysis
Xbrane Biopharma AB
―
Elicera Therapeutics AB
―
Ascelia Pharma AB
―
IRLAB Therapeutics AB Class A
―
Immunicum AB
―